SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing significant volatility and community debate after pulling its compounded GLP-1 drug amid a patent infringement lawsuit from Novo Nordisk and increased regulatory scrutiny. Investors are sharply divided between calls for a short squeeze and a rebound from oversold levels, and predictions of further downside due to ongoing legal and business model challenges.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending due to its all-stock acquisition of Valaris (VAL), a strategic consolidation that the community largely views as enhancing its market leadership and pricing power in an anticipated offshore drilling upcycle, though some express concerns over share dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending due to a significant stock drop following its Q4 earnings report, which, despite showing profitability and prudent risk management, included a revenue miss and cautious guidance. The community is actively debating if the sell-off is an overreaction, viewing it as a potential buying opportunity given the company's strong fundamentals and AI-powered model, while others remain concerned about the broader fintech sector's volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is currently trending after its stock dramatically dropped following news of an SEC review into its accounting practices, reduced guidance, and the departure of its CFO and General Counsel. The community is sharply divided, with some calling it an extreme "overreaction" and a unique "buy-the-dip" opportunity, while others express severe concerns about potential financial improprieties, urging investors to "stay away" until more clarity emerges.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as community discussion heats up around the recent inauguration of its Eagle Line, a significant step toward scalable solid-state battery production. While bulls anticipate potential OEM partnership announcements and licensing deals, others express frustration over the stock's performance and await concrete revenue details from the upcoming earnings report.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as Morgan Stanley initiates coverage with an Overweight rating and a $37 price target, validating its strategic pivot to AI/HPC data centers amidst increasing hyperscaler capital expenditure. The community is actively discussing potential for a significant short squeeze and further contracts with major tech partners.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing a sharp sell-off after issuing a weaker-than-expected revenue outlook and withdrawing its long-term targets, intensifying broader market fears about AI disruption to the traditional software sector. Despite beating Q4 earnings, the community is divided between those viewing the steep decline as an overreaction and a buying opportunity, and others who believe AI poses a fundamental threat to the SaaS business model.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending following a significant stock drop after its Q4 2025 earnings reported losses and missed revenue expectations. However, community discussion is divided, with many bullish investors highlighting the company's projected brighter 2026 outlook, the anticipated benefit from an expiring slab contract, and ongoing strategic partnership talks with POSCO as potential catalysts for a turnaround.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as the community discusses its strategic acquisition of StereoLabs, which creates a unified lidar and camera platform for Physical AI applications. This move is largely seen as strengthening Ouster's market leadership and accelerating its path to profitability through StereoLabs' EBITDA-positive business.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending following a puzzling stock dip, which occurred despite strong earnings and raised guidance, prompting community discussion about whether an overreaction to its Super Bowl commercial or broader market sentiment is creating a 'buying opportunity'.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Is The Market Feeling About CalciMedica Inc?

<ul class="summary-bullets"><li>According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;</li><li>There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.</li><li>Oppenheimer sees the stock as oversold on today's news and "significantly undervalued."</li></ul>CalciMedica (CALC) shares closed down 76% and edged further 4% lower after-hours on Wednesday after the company said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.<h2 class="st-heading-2">Rationale For Discontinuation</h2>The biopharmaceutical company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/calcimedica-announces-discontinuation-of-phase-2-kourage-trial-in-aki-following-independent-data-monitoring-committee-recommendation-302671925.html">said</a> that the discontinuation decision followed a recommendation from an independent data monitoring committee that identified a safety concern.According to the company, the committee said that the safety concerns warrant reevaluation of the study design, particularly with respect to patient enrollment criteria. &nbsp;There were no deaths in the trial related to the study drug or any serious adverse events that warranted expedited reporting to the U.S. Food and Drug Administration, the company added.CalciMedica will now perform a review of the clinical data, which will inform how evaluation of Auxora will proceed in acute kidney injuries. &nbsp;"Based on the IDMC's feedback, we will review the unblinded KOURAGE data and explore modifications to the trial design, particularly patient enrollment criteria, that may support further clinical testing of Auxora in patients with AKI," said CEO Rachel Leheny.CalciMedica is also evaluating Auxora in acute pancreatitis and severe COVID-19 pneumonia.<h2 class="st-heading-2">Analyst Take</h2>Oppenheimer on Wednesday said that shares of CALC were oversold after the company announced the discontinuation of the mid-stage trial in patients with kidney injury.Oppenheimer said that it caught up with management following the news, who said the safety concern identified by the independent committee's review of unblinded data "appears to stem not from the drug itself, but from aspects of this particular trial."The firm sees the stock as oversold on today's news and "significantly undervalued." Even if one removes any revenue potential in AKI from projections, Auxora's derisked $200M opportunity in acute pancreatitis alone supports a favorable outlook, the analyst said.The firm has an ‘Outperform’ rating on CalciMedica shares.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CALC stock jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user voiced hopes for a rebound in share price to sell.<stembedurl>https://www.stocktwits.com/tragusa/message/643195813</stembedurl>Another echoed Oppenheimer and said that the stock is oversold for the news. “This should correct itself either fast or slow but it will correct itself,” they said.<stembedurl>https://www.stocktwits.com/Lay1a/message/643185864</stembedurl><a href="https://stocktwits.com/symbol/CALC">CALC stock</a> has dropped 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q4-2025-earnings/cmyg0wMR40q">Tesla Shares Rise After Hours As EV Giant Commits To Vehicle Autonomy, AI With Cybercab And $2B xAI Investment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

CALC Stock Slumped 76% On Wednesday — Here’s Why

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 

Equity

CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation. 


CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded CalciMedica to a "sell" rating in a report on Saturday...

CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?

CalciMedica (NASDAQ:CALC) Stock Price Down 2.1% - Time to Sell...

Stonepine Capital Management LLC Has $136,000 Stock Position in CalciMedica Inc. $CALC

Stonepine Capital Management LLC lowered its stake in shares of CalciMedica Inc. (NASDAQ:CALC - Free Report) by 76.9% during the second quarter, according to the company in its most recent filing...

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates...

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension CalciMedica Announces Publication in...

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora CalciMedica and Telperian Announce Collaboration to...

CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.

CalciMedica Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$0.6642
Prev Close	$0.6001
Open	$0.6255
Dividend Yield	0.00%
50-Day Moving Average	$4.54
Beta	0.40
Avg. Volume	2.73M
PE Ratio	-0.37

52-Week High	$7.20
52-Week Low	$0.5201
Market Capitalization	$8.65M
EPS (Annual)	-$1.22
Price to Book	-31.92
Revenue Per Employee	$0.00

CALC
CalciMedica Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CALC News

CALCCalciMedica Inc